Literature DB >> 2060084

Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology.

M Hassan1, G Oberg, A N Bekassy, J Aschan, H Ehrsson, P Ljungman, G Lönnerholm, B Smedmyr, A Taube, I Wallin.   

Abstract

Busulphan levels in plasma were measured in 27 patients during conditioning therapy (1 mg/kg x 4 for 4 days) before bone marrow transplantation. The mean minimal concentration found in children aged less than 5 years (237 ng ml-1) was lower than that observed in adults or older children (607 and 573 ng ml-1, respectively). The AUC for the last dose was significantly lower in young children (2.315 h ng ml-1) than in adults or older children (6,134 and 5,937 h ng ml-1, respectively). The elimination half-life for the last dose in young children was shorter (2.05 h) than that in either adults (2.59 h) or older children (2.79 h). When the AUC was normalized for body surface area, the difference between young children and the other groups was smaller but remained statistically significant. The total body clearance was significantly higher in young children (7.3 ml min-1 kg-1) as compared with both older children and adults (3.02 and 2.7 ml min-1 kg-1, respectively). The plasma levels of busulphan showed circadian rhythmicity, especially in young children. The concentration measured during the night in some patients was up to 3-fold that observed during daytime. We conclude that the busulphan dosage for children must be reconsidered and that further studies are urgently needed to develop an optimal therapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2060084     DOI: 10.1007/bf00689702

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  20 in total

1.  Body water compartments in children: changes during growth and related changes in body composition.

Authors:  B FRIIS-HANSEN
Journal:  Pediatrics       Date:  1961-08       Impact factor: 7.124

Review 2.  Clinical pharmacokinetics-pharmacodynamics of anticancer drugs.

Authors:  W E Evans; M V Relling
Journal:  Clin Pharmacokinet       Date:  1989-06       Impact factor: 6.447

3.  Paediatric drug dosing. Bodyweight versus surface area.

Authors:  G M Maxwell
Journal:  Drugs       Date:  1989-02       Impact factor: 9.546

4.  Studies of the development of basic, neutral and acidic isoenzymes of glutathione S-transferase in human liver, adrenal, kidney and spleen.

Authors:  C G Faulder; P A Hirrell; R Hume; R C Strange
Journal:  Biochem J       Date:  1987-01-01       Impact factor: 3.857

Review 5.  Chronobiology: its importance in clinical medicine.

Authors:  D S Minors
Journal:  Clin Sci (Lond)       Date:  1985-10       Impact factor: 6.124

6.  Gas chromatographic determination of busulfan in plasma with electron-capture detection.

Authors:  M Hassan; H Ehrsson
Journal:  J Chromatogr       Date:  1983-10-14

Review 7.  Chronopharmacology.

Authors:  V Marks; J English; W Aherne; J Arendt
Journal:  Clin Biochem       Date:  1985-06       Impact factor: 3.281

Review 8.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

9.  Pharmacokinetic and metabolic studies of high-dose busulphan in adults.

Authors:  M Hassan; G Oberg; H Ehrsson; M Ehrnebo; I Wallin; B Smedmyr; T Tötterman; S Eksborg; B Simonsson
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

10.  Metabolism of 14C-busulfan in isolated perfused rat liver.

Authors:  M Hassan; H Ehrsson
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Jan-Mar       Impact factor: 2.441

View more
  26 in total

Review 1.  Clinical pharmacology in the adolescent oncology patient.

Authors:  Gareth J Veal; Christine M Hartford; Clinton F Stewart
Journal:  J Clin Oncol       Date:  2010-05-03       Impact factor: 44.544

Review 2.  Chronopharmacokinetics. Are they clinically relevant?

Authors:  B Lemmer; B Bruguerolle
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

3.  Test Dose Pharmacokinetics in Pediatric Patients Receiving Once-Daily IV Busulfan Conditioning for Hematopoietic Stem Cell Transplant: A Reliable Approach?

Authors:  Kristina M Brooks; Paul Jarosinski; Thomas Hughes; Elizabeth Kang; Nirali N Shah; John B Le Gall; Dennis D Hickstein; Suk See De Ravin; Jomy M George; Parag Kumar
Journal:  J Clin Pharmacol       Date:  2017-12-14       Impact factor: 3.126

4.  The Role of Pharmacokinetics and Pharmacodynamics in Early Drug Development with reference to the Cyclin-dependent Kinase (Cdk) Inhibitor - Roscovitine.

Authors:  Moustapha Hassan; Hatem Sallam; Zuzana Hassan
Journal:  Sultan Qaboos Univ Med J       Date:  2011-05-15

Review 5.  Plasma concentration monitoring of busulfan: does it improve clinical outcome?

Authors:  J S McCune; J P Gibbs; J T Slattery
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

6.  Gas-chromatographic analysis of busulfan for therapeutic drug monitoring.

Authors:  L Embree; R B Burns; J R Heggie; G L Phillips; D E Reece; J J Spinelli; D O Hartley; N J Hudon; J H Goldie
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Variability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipients.

Authors:  Christa E Nath; John W Earl; Nalini Pati; Katherine Stephen; Peter J Shaw
Journal:  Br J Clin Pharmacol       Date:  2008-03-13       Impact factor: 4.335

8.  Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation.

Authors:  G Vassal; S Koscielny; D Challine; D Valteau-Couanet; I Boland; A Deroussent; J Lemerle; A Gouyette; O Hartmann
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

9.  Exposure equivalence between IV (0.8 mg/kg) and oral (1 mg/kg) busulfan in adult patients.

Authors:  F Léger; L Nguyen; C Puozzo
Journal:  Eur J Clin Pharmacol       Date:  2009-05-08       Impact factor: 2.953

Review 10.  Oral chemotherapy agents in the treatment of leukaemia.

Authors:  R B Geller; S P Dix
Journal:  Drugs       Date:  1999       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.